Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursolic Acid in Metabolic Syndrome
NCT02337933Phase 2Completed
- Sponsor
- Universidad de Guadalajara
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic syndrome comparing Ursolic acid with Placebo (2 arms). Primary endpoints: Total Insulin Sensitivity (Matsuda Index) at 12 weeks, Waist Circumference at 12 weeks and 5 more. Started Sep 2014; status: completed.
02
Drugs
ursolic acid
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT02337933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337933.